Title : Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL.

Pub. Date : 2021 Mar

PMID : 33483276






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: The R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is the standard therapy for patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide DNA damage inducible transcript 3 Homo sapiens